Ultragenyx Pharmaceutical Inc. (RARE) is a publicly traded Healthcare sector company. As of October 8, 2026, RARE trades at $15.02 with a market cap of $1.43B and a P/E ratio of -2.61. RARE moved +0.57% today. Year to date, RARE is -36.91%; over the trailing twelve months it is -49.93%. Its 52-week range spans $12.73 to $46.27. Analyst consensus is buy with an average price target of $28.47. Rallies surfaces RARE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for RARE, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $15.02 |
| Market Cap | $1.43B |
| P/E Ratio | -2.61 |
| EPS | $-5.82 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.27 |
| 52-Week Low | $12.73 |
| Volume | 1.53M |
| Avg Volume | 0 |
| Revenue (TTM) | $717.21M |
| Net Income | $-585.97M |
| Gross Margin | 0.00% |
20 analysts cover RARE: 0 strong buy, 10 buy, 10 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $28.47.